USA flag logo/image

An Official Website of the United States Government

Improving self delivering properties of RNAi compounds through medicinal…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43GM096548
Solicitation Year:
2011
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA10-050
Small Business Information
RXI PHARMACEUTICALS CORPORATION
1500 West Park Drive Suite 210 Westborough, MA 01581-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Improving self delivering properties of RNAi compounds through medicinal chemistr
Agency: HHS
Contract: 1R43GM096548-01
Award Amount: $273,824.00
 

Abstract:

DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant therapeutic paradigm, the ability to apply this technology to human disease has been impeded by the absence of efficient and non-toxic in vivo delivery systems. We recently developed a novel configuration of covalently modified RNAi compounds that do not require a delivery vehicle to enter cells and have improved pharmacology compared to traditional siRNAs. We term these compounds self-delivering rxRNA or sd-rxRNA. The objective of this proposal is to synthesize a novel panel of second generation sd- rxRNA compounds with improved potency and pharmacology by incorporating modified nucleotide bases with lipophilic moieties. A panel of lipophilically modified nucleotide phosphoramidites (pre-cursor monomers) using position 5 of a uracil willbe synthesized for initial screening. These lipophilic monomers will be incorporated into an array of RNAi compounds that will be tested for enhanced potency in biological systems. Completion of this project is expected to develop a next generation of self-delivering rxRNA compounds with at least an order of magnitude better potency and improved pharmacology that can be used to develop RNAi drug candidates in multiple therapeutic areas. PUBLIC HEALTH RELEVANCE: RNAi (RNA interference) has the potential to treat human disease by down regulating disease causing genes; however, efficient delivery to diseased tissue is a major road block for therapeutic development of RNAi. We have recently developed chemically modified RNAi compounds that enter cells invivo ( self-delivering RNAi compounds). By incorporating lipophilic modified nucleotide bases, this project is expected to provide more potent self-delivering rxRNA designs with improved pharmacology for clinical applications.

Principal Investigator:

Kevin Fettes
508-929-3650
kfettes@rxipharma.com

Business Contact:

Margaret Halfpenny
508-929-3650
mhalfpenny@rxipharma.com
Small Business Information at Submission:

RXI PHARMACEUTICALS CORPORATION
60 PRESCOTT ST WORCESTER, MA -

EIN/Tax ID: 120809951
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No